Why it matters: Osteal Therapeutics, a clinical-stage biopharmaceutical company focused on orthopedic infections, is making its first foray into Washington lobbying. The company has assembled a team with deep healthcare policy expertise and significant Republican congressional connections as Congress debates medical research funding and FDA oversight.

By the numbers

Osteal has hired five lobbyists from McGuireWoods Consulting LLC for its inaugural 2025 lobbying registration. The team includes Stephanie A. Kennan, who brings 20 years of healthcare lobbying experience and prior work for Senator Ron Wyden on health policy, along with Scott G. Binkley and Clayton T. Cox, both former legislative directors for Republican House members involved in appropriations and healthcare matters. Melissa A. Bair and Jeremy L. Green round out the team.

The agenda

Osteal’s lobbying will focus on “Medical/Disease Research/Clinical Labs” and “general federal government relations.” The company develops treatments for periprosthetic joint infections following joint replacement surgery. While they haven’t specified particular legislation, they operate in an environment where Congress is actively debating NIH and FDA funding levels, medical research priorities, and domestic biopharmaceutical manufacturing policies.

Between the lines

Osteal’s timing coincides with significant congressional activity surrounding its core interests. Multiple lawmakers, including Senators Patty Murray and Susan Collins, have opposed budget cuts to NIH and FDA that could impact medical research funding. Furthermore, House hearings on “Made in America” manufacturing and biosimilar market competition indicate a continued focus on domestic drug production and regulatory streamlining—essential issues for a clinical-stage company preparing for commercialization. The House Energy and Commerce Committee’s supply chain hearing specifically addressed vulnerabilities in pharmaceutical manufacturing that directly affect companies like Osteal.

The bottom line

Osteal’s entry into lobbying reflects the company’s preparation for the regulatory and policy challenges that come with bringing new treatments to market, especially as Congress considers funding levels for agencies critical to drug approval and medical research.

Spot something wrong? Report an issue with this article